2-(4-(4-methoxyphenethoxy)phenyl)ethan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(4-(4-methoxyphenethoxy)phenyl)ethan-1-ol
• 英文别名: 2-[4-[2-(4-Methoxyphenyl)ethoxy]phenyl]ethanol；2-[4-[2-(4-methoxyphenyl)ethoxy]phenyl]ethanol
• 化学式: C₁₇H₂₀O₃
• 分子量: 272.344
• InChiKey: JINMKYDGZICTIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-(4-methoxyphenethoxy)phenyl)ethan-1-ol 在 三溴化磷 、 三乙胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 3-((4-(4-methoxyphenethoxy)phenethyl)amino)benzoic acid
  参考文献：
  名称：

  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

  摘要：

  Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

  DOI：

  10.1021/acs.jmedchem.9b01189
• 作为产物：
  描述：

  对甲氧基苯乙醇 在 三溴化磷 、 potassium carbonate 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-(4-methoxyphenethoxy)phenyl)ethan-1-ol
  参考文献：
  名称：

  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

  摘要：

  Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

  DOI：

  10.1021/acs.jmedchem.9b01189

文献信息

• [EN] SOCE INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] INHIBITEURS DE SOCE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：INST NAT SANTE RECH MED

  公开号：WO2021233994A1

  公开（公告）日：2021-11-25

  The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.

  本发明提供了一种作为治疗剂在各种应用中有用的SOCE抑制剂。本发明还涉及包含这种SOCE抑制剂的药物组合物、产品和试剂盒，以及在治疗各种疾病中使用SOCE抑制剂的方法。
• SOCE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Centre Hospitalier Régional et Universitaire de Brest

  公开号：EP3912972A1

  公开（公告）日：2021-11-24

  The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.

  本发明提供了在各种应用中可用作治疗剂的 SOCE 抑制剂。本发明还涉及包含此类 SOCE 抑制剂的药物组合物、产品和试剂盒，以及使用 SOCE 抑制剂治疗各种疾病的方法。